David Tabatadze

Dr. Tabatadze cofounded ZATA in partnership with Dr. Paul Zamecnik in 2008 and serves as the President since then. He has a PhD in oligotherapeutics and a MS in organic chemistry. In the early 2000s, he co-invented a gene insertion construct for the correction of the mutated Cystic Fibrosis gene at Massachusetts General Hospital. He is a major architect and leader of the development of modern oligonucleotides with improved therapeutic properties while also overseeing ZATA’s current anti-pathogen program.